FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes morpholine derivative of the formula (I) or its pharmaceutically acceptable salt where R1 is taken among group including: (1) hydrogen atom; (2) C1-6-alkyl that is unsubtituted or substituted with phenyl or heterocycle where heterocycle is taken among group including imidazolyl or triazolyl and where heterocycle is unsubstituted or substituted with oxo-group; each of R2 and R3 means hydrogen atom; R6, R7, R8 are taken independently among group including: (1) hydrogen atom; (2) hydrogen atom, C1-6-alkyl substituted with halogen atom and (3) halogen atom; R11, R12, R13 are taken independently among hydrogen and halogen atom; X means -O-; Y means -O-; Z represents -alkyl. Novel compounds are antagonists of tachykinin receptors. Invention describes also pharmaceutical composition comprising effective dose of compound by claim 1. EFFECT: valuable medicinal properties of compound. 14 cl
Title |
Year |
Author |
Number |
SUBSTITUTED MORPHOLINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF COUNTERACTION TO SUBSTANCE P OR INHIBITION OF NEUROKININ-1 RECEPTORS |
1995 |
- Konrad P. Dorn
- Dzheffri Dzh. Khejl
- Mal'Kol'M Makkoss
- Sander G. Mills
|
RU2170233C2 |
SUBSTITUTED HETEROCYCLES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION FOR BLOCKADE OF NEUROKININ-1 RECEPTORS IN MAMMALS, METHOD OF BLOCKADE OF NEUROKININ-1 RECEPTORS IN MAMMALS |
1993 |
- Konrad P.Dorn
- Dzheffri Dzh.Khejl
- Mal'Kol'M Mehkkoss
- Sander Dzh.Millz
- Tamara Lehdduvakhetti
- Shrenik K.Shakh
|
RU2140914C1 |
SUBSTITUTED MORPHOLINE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON SAID, METHOD OF DECREASE OF TACHIKININ LEVEL IN TREATMENT OR PROPHYLAXIS OF PHYSIOLOGICAL STATES ASSOCIATED WITH TACHIKININ EXCESS |
1994 |
- Rejmond Bejker
- Timoti Kharrison
- Angus Mjurrej Makled
- Ehndrju Pehjt Ouvens
- Ehjlin Mehri S'Juard
- Kristofer Dzhon Svejn
- Martin Richard Till
|
RU2131426C1 |
PROCESS OF OBTAINING 5-[[2 (R)-[1 (R)-[3,5-BIS(TRIFLUOROMETHYL) PHENYL]ETHOXY]-3(8)-(4-FLUOROPHENYL)-4-MORPHOLINYL]METHYL]-1,2-DIHYDRO-3H-1,2,4-TRIAZOLE-3-ONE |
2003 |
- Khaffman Mark
- Kaba Makhmud S.
- Pehjak Dzhozef F.
- Khehndz Dehvid
|
RU2326879C2 |
COMBINATION OF HIV-PROTEASE INHIBITOR WITH OTHER ANTIVIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON SAID AND METHOD OF PHARMACEUTICAL COMPOSITION PREPARING |
1994 |
- Dzhozef P.Vakka
- Dzhejms P.Gar
- Brjus D.Dorsi
- M.Katarin Khollouehj
- Rehndall V.Khangejt
|
RU2139052C1 |
DERIVATIVES OF 1,2,4-TRIAZOLE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF |
2003 |
- Olson Stiven Kh.
- Balkovets Dzhejms M.
- Zkhu Juping
|
RU2319703C2 |
TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1 |
2003 |
- Uoddell Sherman T.
- Santorelli Dzhina M.
- Maletik Milana M.
- Leeman Aaron G.
- Gu Sin'
- Grehkhem Donal'D U.
- Balkovets Dzhejms M.
- Aster S'Juzan D.
|
RU2360910C2 |
DERIVATIVES OF PIPERAZINYLPENTAMIDE AND PHARMACEUTICAL COMPOSITION FOR INHIBITION OF HIV-PROTEASE ACTIVITY |
1992 |
- Dzhozef P.Vakka
- Brjus D.Dorsi
- Dzhejms P.Guar
- Katrin M.Khollovej
- Rehndell V.Khangejt
|
RU2131416C1 |
TYPE 1 DIACYLGLYCEROL-O-ACYLTRANSFERASE ENZYME INHIBITORS |
2008 |
- Lju Gan
- Sin' Chzhili
- Kim Filip R.
- Sauehrs Ehndrju Dzh.
|
RU2486186C2 |
AKT ACTIVITY INHIBITORS |
2006 |
- Armstrong Donna Dzh.
- Khu Ehssa Kh.
- Kelli Majkl Dzh. Iii
- Lejton Mark Eh.
- Li Ivehj
- Ljan Tszjun'
- Rodzinak Kevin Dzh.
- Rossi Majkl A.
- Sanderson Filip Eh.
- Van Tszjabin
|
RU2421454C2 |